|
1
|
Khan WI and Ghia JE: Gut hormones:
Emerging role in immune activation and inflammation. Clin Exp
Immunol. 161:19–27. 2010.PubMed/NCBI
|
|
2
|
Margolis KG and Gershon MD: Neuropeptides
and inflammatory bowel disease. Curr Opin Gastroenterol.
25:503–511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bampton PA and Dinning PG: High resolution
colonic manometry-what have we learnt?-A review of the literature
2012. Curr Gastroenterol Rep. 15:3282013. View Article : Google Scholar
|
|
4
|
Ameri P and Ferone D: Diffuse endocrine
system, neuroendocrine tumors and immunity: What's new?
Neuroendocrinology. 95:267–276. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Farzi A, Reichmann F and Holzer P: The
homeostatic role of neuropeptide Y in immune function and its
impact on mood and behaviour. Acta Physiol (Oxf). 213:603–627.
2015. View Article : Google Scholar
|
|
6
|
Vona-Davis LC and McFadden DW: NPY family
of hormones: Clinical relevance and potential use in
gastrointestinal disease. Curr Top Med Chem. 7:1710–1720. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wheway J, Herzog H and Mackay F: NPY and
receptors in immune and inflammatory diseases. Curr Top Med Chem.
7:1743–1752. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wheway J, Herzog H and Mackay F: The Y1
receptor for NPY: A key modulator of the adaptive immune system.
Peptides. 28:453–458. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wheway J, Mackay CR, Newton RA, Sainsbury
A, Boey D, Herzog H and Mackay F: A fundamental bimodal role for
neuropeptide Y1 receptor in the immune system. J Exp Med.
202:1527–1538. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
El-Salhy M, Suhr O and Danielsson A:
Peptide YY in gastrointestinal disorders. Peptides. 23:397–402.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
El-Salhy M, Mazzawi T, Gundersen D,
Hatlebakk JG and Hausken T: The role of peptide YY in
gastrointestinal diseases and disorders (Review). Int J Mol Med.
31:275–282. 2013.PubMed/NCBI
|
|
12
|
El-Salhy M and Hausken T: The role of the
neuropeptide Y (NPY) family in he pathophysiology of inflammatory
bowel disease (IBD). Neuropeptides. 55:137–144. 2015. View Article : Google Scholar
|
|
13
|
El-Salhy M, Danielsson A, Stenling R and
Grimelius L: Colonic endocrine cells in inflammatory bowel disease.
J Intern Med. 242:413–419. 1997. View Article : Google Scholar
|
|
14
|
El-Salhy M, Gundersen D, Hatlebakk JG and
Hausken T: Chromogranin a cell density as a diagnostic marker for
lymphocytic colitis. Dig Dis Sci. 57:3154–3159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
El-Salhy M, Gundersen D, Hatlebakk JG and
Hausken T: High densities of serotonin and peptide YY cells in the
colon of patients with lymphocytic colitis. World J Gastroenterol.
18:6070–6075. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
El-Salhy M, Lomholt-Beck B and Gundersen
TD: High chromogranin A cell density in the colon of patients with
lymphocytic colitis. Mol Med Rep. 4:603–605. 2011.PubMed/NCBI
|
|
17
|
Moran GW, Pennock J and McLaughlin JT:
Enteroendocrine cells in terminal ileal Crohn's disease. J Crohns
Colitis. 6:871–880. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moran GW, Leslie FC and McLaughlin JT:
Crohn's disease affecting the small bowel is associated with
reduced appetite and elevated levels of circulating gut peptides.
Clin Nutr. 32:404–411. 2013. View Article : Google Scholar
|
|
19
|
Besterman HS, Mallinson CN, Modigliani R,
Christofides ND, Pera A, Ponti V, Sarson DL and Bloom SR: Gut
hormones in inflammatory bowel disease. Scand J Gastroenterol.
18:845–852. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hirotani Y, Mikajiri K, Ikeda K, Myotoku M
and Kurokawa N: Changes of the peptide YY levels in the intestinal
tissue of rats with experimental colitis following oral
administration of mesalazine and prednisolone. Yakugaku Zasshi.
128:1347–1353. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tari A, Teshima H, Sumii K, Haruma K,
Ohgoshi H, Yoshihara M, Kajiyama G and Miyachi Y: Peptide YY
abnormalities in patients with ulcerative colitis. Jpn J Med.
27:49–55. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sciola V, Massironi S, Conte D, Caprioli
F, Ferrero S, Ciafardini C, Peracchi M, Bardella MT and Piodi L:
Plasma chromogranin a in patients with inflammatory bowel disease.
Inflamm Bowel Dis. 15:867–871. 2009. View Article : Google Scholar
|
|
23
|
Bishop AE, Pietroletti R, Taat CW,
Brummelkamp WH and Polak JM: Increased populations of endocrine
cells in Crohn's ileitis. Virchows Arch A Pathol Anat Histopathol.
410:391–396. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Manocha M and Khan WI: Serotonin and GI
Disorders: An update on clinical and experimental studies. Clin
Transl Gastroenterol. 3:e132012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stoyanova II and Gulubova MV: Mast cells
and inflammatory mediators in chronic ulcerative colitis. Acta
Histochem. 104:185–192. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamamoto H, Morise K, Kusugami K, Furusawa
A, Konagaya T, Nishio Y, Kaneko H, Uchida K, Nagai H, Mitsuma T and
Nagura H: Abnormal neuropeptide concentration in rectal mucosa of
patients with inflammatory bowel disease. J Gastroenterol.
31:525–532. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Payer J, Huorka M, Duris I, Mikulecky M,
Kratochvílová H, Ondrejka P and Lukác L: Plasma somatostatin levels
in ulcerative colitis. Hepatogastroenterology. 41:552–553.
1994.PubMed/NCBI
|
|
28
|
Watanabe T, Kubota Y, Sawada T and Muto T:
Distribution and quantification of somatostatin in inflammatory
disease. Dis Colon Rectum. 35:488–494. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Koch TR, Carney JA, Morris VA and Go VL:
Somatostatin in the idiopathic inflammatory bowel diseases. Dis
Colon Rectum. 31:198–203. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
El-Sahy M and Hatlebakk JG: Changes in
endocrine and immune cells following colitis induction by TNBS in
rats. Mol Med Rep. In press.
|
|
31
|
Takeiri M, Tachibana M, Kaneda A, Ito A,
Ishikawa Y, Nishiyama S, Goto R, Yamashita K, Shibasaki S, Hirokata
G, et al: Inhibition of macrophage activation and suppression of
graft rejection by DTCM-glutarimide, a novel piperidine derived
from the antibiotic 9-methylstreptimidone. Inflamm Res. 60:879–888.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
El-Salhy M, Umezawa K, Gilja OH, Hatlebakk
JG, Gundersen D and Hausken T: Amelioration of Severe TNBS Induced
colitis by novel AP-1 and NF-κB inhibitors in rats. Scientfic World
Journal. 2014:8138042014.
|
|
33
|
Umezawa K, Ariga A and Matsumoto N:
Naturally occurring and synthetic inhibitors of NF-kappaB
functions. Anticancer Drug Des. 15:239–244. 2000.
|
|
34
|
Umezawa K: Possible role of peritoneal
NF-kappaB in peripheral inflammation and cancer: Lessons from the
inhibitor DHMEQ. Biomed Pharmacother. 65:252–259. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Funakoshi T, Yamashita K, Ichikawa N,
Fukai M, Suzuki T, Goto R, Oura T, Kobayashi N, Katsurada T,
Ichihara S, et al: A novel NF-kappaB inhibitor,
dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic
injury in mice. J Crohns Colitis. 6:215–225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
El-Salhy M, Wendelbo IH, Gundersen D,
Hatlebakk JG and Hausken T: Evaluation of the usefulness of
colonoscopy with mucosal biopsies in the follow-up of TNBS-induced
colitis in rats. Mol Med Rep. 8:446–450. 2013.PubMed/NCBI
|
|
37
|
Ota E, Takeiri M, Tachibana M, Ishikawa Y,
Umezawa K and Nishiyama S: Synthesis and biological evaluation of
molecular probes based on the 9-methylstreptimidone derivative
DTCM-glutarimide. Bioorg Med Chem Lett. 22:164–167. 2012.
View Article : Google Scholar
|
|
38
|
Ishikawa Y, Tachibana M, Matsui C, Obata
R, Umezawa K and Nishiyama S: Synthesis and biological evaluation
on novel analogs of 9-methylstreptimidone, an inhibitor of
NF-kappaB. Bioorg Med Chem Lett. 19:1726–1728. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ueki S, Yamashita K, Aoyagi T, Haga S,
Suzuki T, Itoh T, Taniguchi M, Shimamura T, Furukawa H, Ozaki M, et
al: Control of allograft rejection by applying a novel nuclear
factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Transplantation. 82:1720–1727. 2006. View Article : Google Scholar
|
|
40
|
Matsumoto N, Ariga A, To-e S, Nakamura H,
Agata N, Hirano S, Inoue J and Umezawa K: Synthesis of NF-kappaB
activation inhibitors derived from epoxyquinomicin C. Bioorg Med
Chem Lett. 10:865–869. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Umezawa N, Matsumoto N, Iwama S, Kato N
and Higuchi T: Facile synthesis of peptide-porphyrin conjugates:
Towards artificial catalase. Bioorg Med Chem. 18:6340–6350. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hunter MM, Wang A, Hirota CL and McKay DM:
Neutralizing anti-IL-10 antibody blocks the protective effect of
tapeworm infection in a murine model of chemically induced colitis.
J Immunol. 174:7368–7375. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pang XH, Li TK, Xie Q, He FQ, Cui de J,
Chen YQ, Huang XL and Gan HT: Amelioration of dextran sulfate
sodium-induced colitis by neuropeptide Y antisense
oligodeoxynucleotide. Int J Colorectal Dis. 25:1047–1053. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bohorquez DV, Chandra R, Samsa LA, Vigna
SR and Liddle RA: Characterization of basal pseudopod-like
processes in ileal and colonic PYY cells. J Mol Histol. 42:3–13.
2011. View Article : Google Scholar
|
|
45
|
Bohórquez DV, Samsa LA, Roholt A,
Medicetty S, Chandra R and Liddle RA: An enteroendocrine
cell-enteric glia connection revealed by 3D electron microscopy.
PloS one. 9:e898812014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bohórquez DV, Shahid RA, Erdmann A, Kreger
AM, Wang Y, Calakos N, Wang F and Liddle RA: Neuroepithelial
circuit formed by innervation of sensory enteroendocrine cells. J
Clin Invest. 125:782–786. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ghia JE, Li N, Wang H, Collins M, Deng Y,
El-Sharkawy RT, Côté F, Mallet J and Khan WI: Serotonin has a key
role in pathogenesis of experimental colitis. Gastroenterology.
137:1649–1660. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dryden S, Wang Q, Frankish HM, Pickavance
L and Williams G: The serotonin (5-HT) antagonist methysergide
increases neuropeptide Y (NPY) synthesis and secretion in the
hypothalamus of the rat. Brain Res. 699:12–18. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Spångeus A, Forsgren S and el-Salhy M:
Does diabetic state affect co-localization of peptide YY and
enteroglucagon in colonic endocrine cells? Histol Histopathol.
15:37–41. 2000.PubMed/NCBI
|
|
50
|
Pyarokhil AH, Ishihara M, Sasaki M and
Kitamura N: The developmental plasticity of colocalization pattern
of peptide YY and glucagon-like peptide-1 in the endocrine cells of
bovine rectum. Biomed Res. 33:35–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bertrand PP and Bertrand RL: Serotonin
release and uptake in the gastrointestinal tract. Auton Neurosci.
153:47–57. 2010. View Article : Google Scholar
|
|
52
|
Qian BF, El-Salhy M, Melgar S, Hammarström
ML and Danielsson A: Neuroendocrine changes in colon of mice with a
disrupted IL-2 gene. Clin Exp Immunol. 120:424–433. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Oshima S, Fujimura M and Fukimiya M:
Changes in number of serotonin-containing cells and serotonin
levels in the intestinal mucosa of rats with colitis induced by
dextran sodium sulfate. Histochem Cell Biol. 112:257–263. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Spiller R: Serotonin and GI clinical
disorders. Neuropharmacology. 55:1072–1080. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Egger M, Beer AG, Theurl M, Schgoer W,
Hotter B, Tatarczyk T, Vasiljevic D, Frauscher S, Marksteiner J,
Patsch JR, et al: Monocyte migration: A novel effect and signaling
pathways of catestatin. Eur J Pharmacol. 598:104–111. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Feistritzer C, Mosheimer BA, Colleselli D,
Wiedermann CJ and Kähler CM: Effects of the neuropeptide
secretoneurin on natural killer cell migration and cytokine
release. Regul Pept. 126:195–201. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ferrero E, Magni E, Curnis F, Villa A,
Ferrero ME and Corti A: Regulation of endothelial cell shape and
barrier function by chromogranin A. Ann N Y Acad Sci. 971:355–358.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang H, Steeds J, Motomura Y, Deng Y,
Verma-Gandhu M, El-Sharkawy RT, McLaughlin JT, Grencis RK and Khan
WI: CD4+ T cell-mediated immunological control of enterochromaffin
cell hyperplasia and 5-hydroxytryptamine production in enteric
infection. Gut. 56:949–957. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Cloez-Tayarani I and Changeux JP: Nicotine
and serotonin in immune regulation and inflammatory processes: A
perspective. J Leukoc Biol. 81:599–606. 2007. View Article : Google Scholar
|
|
60
|
Stefulj J, Cicin-Sain L, Schauenstein K
and Jernej B: Serotonin and immune response: Effect of the amine on
in vitro proliferation of rat lymphocytes. Neuroimmunomodulation.
9:103–108. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Betten A, Dahlgren C, Hermodsson S and
Hellstrand K: Serotonin protects NK cells against oxidatively
induced functional inhibition and apoptosis. J Leukoc Biol.
70:65–72. 2001.PubMed/NCBI
|
|
62
|
Laberge S, Cruikshank WW, Beer DJ and
Center DM: Secretion of IL-16 (lymphocyte chemoattractant factor)
from serotonin-stimulated CD8+ T cells in vitro. J Immunol.
156:310–315. 1996.PubMed/NCBI
|
|
63
|
Soga F, Katoh N, Inoue T and Kishimoto S:
Serotonin activates human monocytes and prevents apoptosis. J
Invest Dermatol. 127:1947–1955. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Di Sabatino A, Volta U, Salvatore C,
Biancheri P, Caio G, De Giorgio R, Di Stefano M and Corazza GR:
Small amounts of gluten in subjects with suspected nonceliac gluten
sensitivity: A randomized, double-blind, placebo-controlled,
cross-over trial. Clin Gastroenterol Hepatol. 13:1604–1612. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Macia L, Yulyaningsih E, Pangon L, Nguyen
AD, Lin S, Shi YC, Zhang L, Bijker M, Grey S, Mackay F, et al:
Neuropeptide Y1 receptor in immune cells regulates inflammation and
insulin resistance associated with diet-induced obesity. Diabetes.
61:3228–3238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
De la Fuente M, Bernaez I, Del Rio M and
Hernanz A: Stimulation of murine peritoneal macrophage functions by
neuropeptide Y and peptide YY. Involvement of protein kinase C.
Immunology. 80:259–265. 1993.PubMed/NCBI
|
|
67
|
Ferone D, Resmini E, Boschetti M, Arvigo
M, Albanese V, Ceresola E, Pivonello R, Albertelli M, Bianchi F,
Giusti M and Minuto F: Potential indications for somatostatin
analogues: Immune system and limphoproliferative disorders. J
Endocrinol Invest. 28(11 Supply International): 111–117. 2005.
|
|
68
|
ten Bokum AM, Hofland LJ and van Hagen PM:
Somatostatin and somatostatin receptors in the immune system: A
review. Eur Cytokine Netw. 11:161–176. 2000.PubMed/NCBI
|
|
69
|
Ferone D, Pivonello R, Kwekkeboom DJ,
Gatto F, Ameri P, Colao A, de Krijger RR, Minuto F, Lamberts SW,
van Hagen PM and Hofland LJ: Immunohistochemical localization and
quantitative expression of somatostatin receptors in normal human
spleen and thymus: Implications for the in vivo visualization
during somatostatin receptor scintigraphy. J Endocrinol Invest.
35:528–534. 2012.
|
|
70
|
Ferone D, Pivonello R, Van Hagen PM, Dalm
VA, Lichtenauer-Kaligis EG, Waaijers M, Van Koetsveld PM, Mooy DM,
Colao A, Minuto F, et al: Quantitative and functional expression of
somatostatin receptor subtypes in human thymocytes. Am J Physiol
Endocrinol Metab. 283:E1056–E1066. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Dalm VA, van Hagen PM, van Koetsveld PM,
Achilefu S, Houtsmuller AB, Pols DH, van der Lely AJ, Lamberts SW
and Hofland LJ: Expression of somatostatin, cortistatin and
soma-tostatin receptors in human monocytes, macrophages and
dendritic cells. Am J Physiol Endocrinol Metab. 285:E344–E353.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Lichtenauer-Kaligis EG, Dalm VA, Oomen SP,
Mooij DM, van Hagen PM, Lamberts SW and Hofland LJ: Differential
expression of somatostatin receptor subtypes in human peripheral
blood mononuclear cell subsets. Eur J Endocrinol. 150:565–577.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Armani C, Catalani E, Balbarini A, Bagnoli
P and Cervia D: Expression, pharmacology and functional role of
somatostatin receptor subtypes 1 and 2 in human macrophages. J
Leukoc Biol. 81:845–855. 2007. View Article : Google Scholar
|
|
74
|
Taniyama Y, Suzuki T, Mikami Y, Moriya T,
Satomi S and Sasano H: Systemic distribution of somatostatin
receptor subtypes in human: An immunohistochemical study. Endocrine
J. 52:605–611. 2005. View Article : Google Scholar
|
|
75
|
Hagströmer L, Emtestam L, Stridsberg M and
Talme T: Expression pattern of somatostatin receptor subtypes 1–5
in human skin: An immunohistochemical study of healthy subjects and
patients with psoriasis or atopic dermatitis. Exp Dermatol.
15:950–957. 2006. View Article : Google Scholar
|
|
76
|
Talme T, Ivanoff J, Hägglund M, Van
Neerven RJ, Ivanoff A and Sundqvist KG: Somatostatin receptor
(SSTR) expression and function in normal and leukaemic T-cells.
Evidence for selective effects on adhesion to extracellular matrix
components via SSTR2 and/or 3. Clin Exp Immunol. 125:71–79. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Rosskopf D, Schürks M, Manthey I, Joisten
M, Busch S and Siffert W: Signal transduction of somatostatin in
human B lymphoblasts. American journal of physiology. Cell
physiology. 284:C179–C190. 2003. View Article : Google Scholar
|
|
78
|
Casnici C, Lattuada D, Perego C, Franco P
and Marelli O: Inhibitory effect of somatostatin on human T
lymphocytes proliferation. Int J Immunopharmacol. 19:721–727. 1997.
View Article : Google Scholar
|
|
79
|
Radosević-Stasić B, Trobonjaca Z, Lucin P,
Cuk M, Polić B and Rukavina D: Immunosuppressive and
antiproliferative effects of somatostatin analog SMS 201–995. Int J
Neurosci. 81:283–297. 1995. View Article : Google Scholar
|
|
80
|
Sirianni MC, Annibale B, Fais S and Delle
Fave G: Inhibitory effect of somatostatin-14 and some analogues on
human natural killer cell activity. Peptides. 15:1033–1036. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Helyes Z, Elekes K, Németh J, Pozsgai G,
Sándor K, Kereskai L, Börzsei R, Pintér E, Szabó A and Szolcsányi
J: Role of transient receptor potential vanilloid 1 receptors in
endotoxin-induced airway inflammation in the mouse. Am J Physiol
Lung Cell Mol Physiol. 292:L1173–L1181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Helyes Z, Pintér E, Sándor K, Elekes K,
Bánvölgyi A, Keszthelyi D, Szoke E, Tóth DM, Sándor Z, Kereskai L,
et al: Impaired defense mechanism against inflammation,
hyperalgesia and airway hyperreactivity in somatostatin 4 receptor
gene-deleted mice. Proc Natl Acad Sci USA. 106:13088–13093. 2009.
View Article : Google Scholar
|
|
83
|
El-Salhy M, Seim I, Chopin L, Gundersen D,
Hatlebakk JG and Hausken T: Irritable bowel syndrome: The role of
gut neuroendocrine peptides. Front Biosci (Elite Ed). 4:2783–2800.
2012.
|
|
84
|
El-Salhy M, Gundersen D, Hatlebakk JG and
Hausken T: Irritable bowel syndrome: Diagnosis, pathogenesis and
treatment options. Nova Science Publishers; Inc, New York: 2012
|
|
85
|
El-Salhy M, Gundersen D, Gilja OH,
Hatlebakk JG and Hausken T: Is irritable bowel syndrome an organic
disorder? World J Gastroenterol. 20:384–400. 2014. View Article : Google Scholar : PubMed/NCBI
|
